172 related articles for article (PubMed ID: 36240849)
1. Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma.
Ng CF; Glaspy J; Placencio-Hickok VR; Thomassian S; Gong J; Osipov A; Hendifar AE; Moshayedi N
J Natl Compr Canc Netw; 2022 Oct; 20(10):1076-1079. PubMed ID: 36240849
[TBL] [Abstract][Full Text] [Related]
2. Stage 4 pancreatic adenocarcinoma harbouring an
Poon D; Tan MH; Khor D
BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34511423
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of fibroblast growth factor receptor 2 attenuates proliferation and invasion of pancreatic cancer.
Matsuda Y; Yoshimura H; Suzuki T; Uchida E; Naito Z; Ishiwata T
Cancer Sci; 2014 Sep; 105(9):1212-9. PubMed ID: 24975163
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
5. FGFR2 fusion in metastatic pancreatic ductal adenocarcinoma: Is there hope?
Helal C; Valéry M; Ducreux M; Hollebecque A; Smolenschi C
Eur J Cancer; 2022 Nov; 176():168-170. PubMed ID: 36244195
[No Abstract] [Full Text] [Related]
6. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
7. Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer.
Datta J; Bianchi A; De Castro Silva I; Deshpande NU; Cao LL; Mehra S; Singh S; Rafie C; Sun X; Chen X; Dai X; Colaprico A; Sharma P; Dosch AR; Pillai A; Hosein PJ; Nagathihalli NS; Komanduri KV; Wilson JM; Ban Y; Merchant NB
Oncogene; 2022 Jul; 41(28):3640-3654. PubMed ID: 35701533
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
[TBL] [Abstract][Full Text] [Related]
10. Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib.
de Almeida Carvalho LM; de Oliveira Sapori Avelar S; Haslam A; Gill J; Prasad V
JAMA Netw Open; 2019 Nov; 2(11):e1916091. PubMed ID: 31755953
[TBL] [Abstract][Full Text] [Related]
11. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
12. Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment.
Werba G; Weissinger D; Kawaler EA; Zhao E; Kalfakakou D; Dhara S; Wang L; Lim HB; Oh G; Jing X; Beri N; Khanna L; Gonda T; Oberstein P; Hajdu C; Loomis C; Heguy A; Sherman MH; Lund AW; Welling TH; Dolgalev I; Tsirigos A; Simeone DM
Nat Commun; 2023 Feb; 14(1):797. PubMed ID: 36781852
[TBL] [Abstract][Full Text] [Related]
13. The biological underpinnings of therapeutic resistance in pancreatic cancer.
Beatty GL; Werba G; Lyssiotis CA; Simeone DM
Genes Dev; 2021 Jul; 35(13-14):940-962. PubMed ID: 34117095
[TBL] [Abstract][Full Text] [Related]
14. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): A case report and literature review.
Patel GK; Perry JB; Abdul-Rahim O; Frankel AE; Cameron D; Taylor W; Rocconi RP; Abushahin L; Nelson C; Singh AP; Khushman M
J Cancer Res Ther; 2020; 16(4):950-954. PubMed ID: 32930150
[TBL] [Abstract][Full Text] [Related]
16. Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review.
Wang Y; Wang B; Xiang L; Deng J; Xu B; He P; Pu W; Wang H; Fan Y; Chen H
Front Immunol; 2022; 13():1016647. PubMed ID: 36311715
[TBL] [Abstract][Full Text] [Related]
17. Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.
Roubal K; Myint ZW; Kolesar JM
Am J Health Syst Pharm; 2020 Feb; 77(5):346-351. PubMed ID: 32073123
[TBL] [Abstract][Full Text] [Related]
18. FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer.
Nomura S; Yoshitomi H; Takano S; Shida T; Kobayashi S; Ohtsuka M; Kimura F; Shimizu H; Yoshidome H; Kato A; Miyazaki M
Br J Cancer; 2008 Jul; 99(2):305-13. PubMed ID: 18594526
[TBL] [Abstract][Full Text] [Related]
19. The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC.
Brown M; Zhang W; Yan D; Kenath R; Le L; Wang H; Delitto D; Ostrov D; Robertson K; Liu C; Pham K
PLoS One; 2020; 15(1):e0226917. PubMed ID: 31929540
[TBL] [Abstract][Full Text] [Related]
20. Precision Medicine and Pancreatic Cancer.
George B
Surg Oncol Clin N Am; 2021 Oct; 30(4):693-708. PubMed ID: 34511190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
